

02-09-2022

PRESS RELEASE  
Regulated information



## Adjustment to the rights of the holders of convertible bonds

**Liege, Belgium, 02 September 2022 – 17:45 CET** – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces today that, as a result of the senior secured convertible facilities agreement and conversion agreement entered into by the Company and announced on 8 August 2022<sup>1</sup>, and in accordance with condition 5(b) of the Company's EUR 125,000,000 senior unsecured convertible bonds due 2025 (ISIN: BE6325746855)<sup>2</sup>, the conversion price of the bonds has been adjusted from EUR 25.1917 to EUR 24.5425, effective as of 8 August 2022.

\*\*\*\*\*

### For more information, please contact:

**Benoît Mathieu (IRO)** : +32 473 35 80 18 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**Maud Vanderthommen (Press)** : +32 473 58 61 04 – [press@mithra.com](mailto:press@mithra.com)

### About Mithra

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.*

[www.mithra.com](http://www.mithra.com)

---

<sup>1</sup> [Mithra's press release 08/08/2022](#)

<sup>2</sup> [Mithra's press release 10/12/2020](#)

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

02-09-2022

PRESS RELEASE  
Regulated information

### Important information

*This document is not an offer to sell or a solicitation of an offer to buy (convertible) bonds, shares or other securities of Mithra. The information contained herein is not for release, publication or distribution in or into the United States or in or into Australia, Canada, Japan, South Africa or any other jurisdiction in which such distribution would be prohibited by applicable law.*

---



News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](https://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)